Hayfever season has started three weeks early, experts are warning.
That means that 18 million Brits could see their Easter bank holidays ruined by runny noses and itchy eyes.
It’s all thanks to the unusually warm winter, which saw temperatures soaring to highs of 21’C.
Birch tree pollen – which affects one in four hayfever sufferers, is already being released across the country.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.